Predictive criteria for overall survival and treatment duration of 2nd-line chemotherapy in patients with advanced pancreatic adenocarcinoma (AIO-PAK-0216).

Lutz MP, Ansorge N, Barmashenko G, Bauer H, Burkart C, Decker T, Ettrich T, Fischer von Weikersthal L, Geer T, Gerhardt A, Höfling S, Jacobasch L, Koenigsmann M, Leidig T, Plentz R, Räth S, Reichert D, Schulte M, Schulte N, Schwarzer A, Siegler G, Waldschmidt D, Karthaus M

Open source

DOI: 10.1038/s41416-025-03188-x
Published: 2026 Jan
Container: British journal of cancer
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41416-025-03188-x,
  title = {Predictive criteria for overall survival and treatment duration of 2nd-line chemotherapy in patients with advanced pancreatic adenocarcinoma (AIO-PAK-0216).},
  author = {Lutz MP and Ansorge N and Barmashenko G and Bauer H and Burkart C and Decker T and Ettrich T and Fischer von Weikersthal L and Geer T and Gerhardt A and Höfling S and Jacobasch L and Koenigsmann M and Leidig T and Plentz R and Räth S and Reichert D and Schulte M and Schulte N and Schwarzer A and Siegler G and Waldschmidt D and Karthaus M},
  year = {2026},
  journal = {British journal of cancer},
  doi = {10.1038/s41416-025-03188-x},
  url = {https://doi.org/10.1038/s41416-025-03188-x}
}

RIS

TY  - JOUR
TI  - Predictive criteria for overall survival and treatment duration of 2nd-line chemotherapy in patients with advanced pancreatic adenocarcinoma (AIO-PAK-0216).
AU  - Lutz MP
AU  - Ansorge N
AU  - Barmashenko G
AU  - Bauer H
AU  - Burkart C
AU  - Decker T
AU  - Ettrich T
AU  - Fischer von Weikersthal L
AU  - Geer T
AU  - Gerhardt A
AU  - Höfling S
AU  - Jacobasch L
AU  - Koenigsmann M
AU  - Leidig T
AU  - Plentz R
AU  - Räth S
AU  - Reichert D
AU  - Schulte M
AU  - Schulte N
AU  - Schwarzer A
AU  - Siegler G
AU  - Waldschmidt D
AU  - Karthaus M
PY  - 2026
JO  - British journal of cancer
DO  - 10.1038/s41416-025-03188-x
UR  - https://doi.org/10.1038/s41416-025-03188-x
ER  -

APA

MP, L., N, A., G, B., H, B., C, B., T, D., T, E., L, F. V. W., T, G., A, G., S, H., L, J., M, K., T, L., R, P., S, R., D, R., M, S., N, S., A, S., G, S., D, W., & M, K. (2026). Predictive criteria for overall survival and treatment duration of 2nd-line chemotherapy in patients with advanced pancreatic adenocarcinoma (AIO-PAK-0216).. British journal of cancer. https://doi.org/10.1038/s41416-025-03188-x

Source records

pubmed · retrieved 2026-09-26T02:52:52.602Z